-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Telotristat etiprate, a novel inhibitor of serotonin synthesis for the treatment of carcinoid syndrome
Pablo Lapuerta, Brian Zambrowicz, Doug Fleming, Darren Wheeler & Arthur Sands
Special Report: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Corrigendum: Clinical Investigation (2015) Vol 4, Iss 11.
Corrigendum: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of children with frequently relapsing steroid-sensitive nephrotic syndrome: recent trial results
Marcus R Benz, Burkhard Toenshoff & Lutz T Weber
Clinical Trail Outcomes: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Research integrity in the modern era: current gaps in our knowledge and thinking
Marisa Kardos Garshick and Alexa Boer Kimball
Editorial: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Outcomes of novel trials for cancer cachexia
Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Maria Pipa-Muniz1, Maria Varela, Luisa Gonzalez-Dieguez,Manuel Rodguez
Therapeutic Prospective: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
Rahat Noor, Van A Trinh, Kevin B Kim, Wen-Jen Hwu
Review Article: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
New approaches to the design of sublingual immunotherapy clinical trials
Enrico Compalati, Anthi Rogkakou, Alberto Bordo, Giorgio Walter Canonica, Giovanni Passalacqua
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation
-
Design, findings and implications of the RECORD study program
Lars Carl Borris
Review Article: Clinical Investigation